UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

1800P Breaking chemo-immunotherapy resistance in SCLC-patient derived tumor with novel DDRi combinations

Annals of oncology, 2024-09, Vol.35, p.S1069-S1069

2024

Volltextzugriff (PDF)

1810P MYC expression defines distinct transcriptomic landscape and affects response to DNA-damaging therapies in SCLC

Annals of oncology, 2024-09, Vol.35, p.S1073-S1073

2024

Volltextzugriff (PDF)

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA

ESMO open, 2021-02, Vol.6 (1), p.100041-100041, Article 100041

2021

Volltextzugriff (PDF)

1909P - Evaluation of antibody-dependent cell cytotoxicity (ADCC) in lung cancer cell lines treated with combined anti-EGFR and anti-PD-L1 therapy

Annals of oncology, 2019-10, Vol.30, p.v772-v773

2019

Volltextzugriff (PDF)

Evaluation of antibody-dependent cell cytotoxicity (ADCC) in lung cancer cell lines treated with combined anti-EGFR and anti-PD-L1 therapy

Annals of oncology, 2019-10, Vol.30, p.v772-v773

2019

Volltextzugriff (PDF)

140P MYC subgroups delineate specific transcriptomic landscape and shape response to radiotherapy in SCLC

ESMO open, 2024-10, Vol.9, p.103879, Article 103879

2024

Volltextzugriff (PDF)

Proof of concept on the role of ex vivo lung cancer spheroids, cytokines expression and PBMCs profiling in monitoring disease history and response to treatments

Annals of oncology, 2019-10, Vol.30, p.v776

2019

Volltextzugriff (PDF)

1921P - Proof of concept on the role of ex vivo lung cancer spheroids, cytokines expression and PBMCs profiling in monitoring disease history and response to treatments

Annals of oncology, 2019-10, Vol.30, p.v776-v776

2019

Volltextzugriff (PDF)

204P Maintenance of anti-tumour innate immune response in SCLC with DNA-PK inhibition

ESMO open, 2024-03, Vol.9, p.102777, Article 102777

2024

Volltextzugriff (PDF)

2001P Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy

Annals of oncology, 2023-10, Vol.34, p.S1067-S1067

2023

Volltextzugriff (PDF)

3O Efficacy of the triple combination of Estrogen Receptor, CDK4/6 and PI3K pathway inhibitors in ex-vivo models of breast cancer

Annals of oncology, 2020-09, Vol.31, p.S245-S246

2020

Volltextzugriff (PDF)

168P Effect of sequence treatment of chemotherapy plus radiotherapy activates innate immunity in SCLC

Immuno-oncology technology, 2023-12, Vol.20, p.100627, Article 100627

2023

Volltextzugriff (PDF)

16P Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC

ESMO open, 2023-10, Vol.8 (1), p.101662, Article 101662

2023

Volltextzugriff (PDF)

73P Effect of combination therapy with atezolizumab plus metformin on peripheral immune cells from NSCLC patients

ESMO open, 2023-10, Vol.8 (1), p.101883, Article 101883

2023

Volltextzugriff (PDF)

163P Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: Findings from the CAVE-lung trial

Annals of oncology, 2022-04, Vol.33, p.S107-S108

2022

Volltextzugriff (PDF)

The combination of MEK inhibitor and anti PD-L1: Effects on organoid models from NSCLC biopsies

Annals of oncology, 2018-10, Vol.29, p.viii656-viii656

2018

Volltextzugriff (PDF)

1056P KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC

Annals of oncology, 2022-09, Vol.33, p.S1037-S1038

2022

Volltextzugriff (PDF)

Genomic profiling of non-oncogene-addicted aNSCLC using liquid biopsy. A single institution Italian experience

Annals of oncology, 2019-11, Vol.30, p.vii6

2019

Volltextzugriff (PDF)

155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models

Journal of thoracic oncology, 2018-04, Vol.13 (4), p.S93-S93

2018

Volltextzugriff (PDF)

51PD Effect of MEK inhibition on PDL1 and and on cytokinesproduction profilein NSCLC cell lines and in human lymphocites

Journal of thoracic oncology, 2018-04, Vol.13 (4), p.S27-S27

2018

Volltextzugriff (PDF)

244P DNA-PK inhibition sustains immune activation in SCLC

Immuno-oncology technology, 2022-12, Vol.16, p.100233, Article 100233

2022

Volltextzugriff (PDF)

68P OncoMutational ratio on ctDNA: A potential novel biomarker in NSCLC

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S79-S80

2023

Volltextzugriff (PDF)

1735P SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models

Annals of oncology, 2020-09, Vol.31, p.S1015-S1015

2020

Volltextzugriff (PDF)

1335P Anti-tumour efficacy of cetuximab plus avelumab in NSCLC through induction of ADCC: Final data from CAVE-lung trial

Annals of oncology, 2020-09, Vol.31, p.S858-S859

2020

Volltextzugriff (PDF)

Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer

Annals of oncology, 2019-10, Vol.30, p.v716

2019

Volltextzugriff (PDF)

1 – 25 von 65

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(65)

Sprache

Englisch
(65)

Erscheinungsjahr

n.n

Kollektion

EZB Electronic Journals Library
(65)
Journals@Ovid
(53)
MEDLINE
(3)
Ingenta
(3)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(1)
Elsevier ScienceDirect Journals Complete
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

1800P Breaking chemo-immunotherapy resistance in SCLC-patient derived tumor with novel DDRi combinations

1810P MYC expression defines distinct transcriptomic landscape and affects response to DNA-damaging therapies in SCLC

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA

1909P - Evaluation of antibody-dependent cell cytotoxicity (ADCC) in lung cancer cell lines treated with combined anti-EGFR and anti-PD-L1 therapy

Evaluation of antibody-dependent cell cytotoxicity (ADCC) in lung cancer cell lines treated with combined anti-EGFR and anti-PD-L1 therapy

140P MYC subgroups delineate specific transcriptomic landscape and shape response to radiotherapy in SCLC

Proof of concept on the role of ex vivo lung cancer spheroids, cytokines expression and PBMCs profiling in monitoring disease history and response to treatments

1921P - Proof of concept on the role of ex vivo lung cancer spheroids, cytokines expression and PBMCs profiling in monitoring disease history and response to treatments

204P Maintenance of anti-tumour innate immune response in SCLC with DNA-PK inhibition

2001P Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy

3O Efficacy of the triple combination of Estrogen Receptor, CDK4/6 and PI3K pathway inhibitors in ex-vivo models of breast cancer

168P Effect of sequence treatment of chemotherapy plus radiotherapy activates innate immunity in SCLC

16P Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC

73P Effect of combination therapy with atezolizumab plus metformin on peripheral immune cells from NSCLC patients

163P Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: Findings from the CAVE-lung trial

The combination of MEK inhibitor and anti PD-L1: Effects on organoid models from NSCLC biopsies

1056P KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC

Genomic profiling of non-oncogene-addicted aNSCLC using liquid biopsy. A single institution Italian experience

155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models

51PD Effect of MEK inhibition on PDL1 and and on cytokinesproduction profilein NSCLC cell lines and in human lymphocites

244P DNA-PK inhibition sustains immune activation in SCLC

68P OncoMutational ratio on ctDNA: A potential novel biomarker in NSCLC

1735P SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models

1335P Anti-tumour efficacy of cetuximab plus avelumab in NSCLC through induction of ADCC: Final data from CAVE-lung trial

Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer

Suchergebnisse filtern